A new market research report on
the Global 3D Printed Drugs market has introduced by KD Market Insights.
The report is dedicated to in-depth industry analysis of the global 3D
Printed Drugs market. The Global 3D Printed
Drugs analysis is broken
down on different segmentation levels including Market BY SCENARIO.
Spritam is the only 3D printed drug which has received FDA
approval. This drug was first available in the market in 2016, and can be used
to treat epilepsy. The potential market for other 3D printed drugs (moderate
growth scenario) is estimated to be $278 million in 2020, and would reach $522
million by 2030, growing at a CAGR of 6.5% from
2020 to 2030. 3D printed drugs are developed by 3D printing technology to treat
patients and children affected with dysphagia. These drugs are highly porous in
nature and disintegrate rapidly, which eliminate the need to directly swallow
the intact high-dose medicine.
The growth of the 3D printed drugs market is
driven by upsurge in demand of instantaneous soluble drugs, rise in geriatric
population, and high adoption of 3D printing technology. In addition, rapid
technological advancements, increase in awareness about the 3D printing, and
improvement in healthcare infrastructure fuel the market growth. However,
factors such as adverse effects related to these drugs, lack of government
regulations for these drugs, and use of 3D printing to develop illegal drugs
are expected to restrain the market growth. Conversely, introduction of 3D
printed drugs by various key vendors in developing nations and increase in
healthcare investment in emerging nations are expected to provide lucrative
opportunities for the market growth in the near future.
The
market is segmented on the basis of Spritam, scenario, and geography. For
Spritam, market is categorized on the basis of geography into U.S. and rest of
North America. On the basis of scenario, the market is categorized into low
growth scenario, moderate growth scenario, and rapid growth scenario.
Geographically, it is analyzed across North America (U.S. and rest of North
America), Europe (UK, Germany, France, Italy, Spain, and rest of Europe),
Asia-Pacific (China, Japan, Australia, and rest of Asia-Pacific), and LAMEA
(Brazil, Saudi Arabia, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
–
The study provides an in-depth analysis of the global 3D printed drugs market
with current trends and future estimations to elucidate the investment pockets.
– Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
– The report offers a quantitative analysis to assist the stakeholders to capitalize on prevailing market opportunities.
– Extensive analysis of different segments facilitates to determine various products available in the market.
– Key players are profiled and their strategies are analyzed thoroughly to predict the competitive market outlook.
– Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
– The report offers a quantitative analysis to assist the stakeholders to capitalize on prevailing market opportunities.
– Extensive analysis of different segments facilitates to determine various products available in the market.
– Key players are profiled and their strategies are analyzed thoroughly to predict the competitive market outlook.
SPRITAM MARKET, BY GEOGRAPHY
–
U.S.
– Rest of World
– Rest of World
OTHER DRUGS POTENTIAL MARKET, BY
SCENARIO
–
Low Growth Scenario
– Moderate Growth Scenario
– Rapid Growth Scenario
– Moderate Growth Scenario
– Rapid Growth Scenario
OTHER DRUGS POTENTIAL MARKET, BY
REGION
–
North America
– – U.S.
– – Rest of North America
– Europe
– – UK
– – Germany
– – France
– – Italy
– – Spain
– – Rest of Europe
– Asia-Pacific
– – Japan
– – China
– – Australia
– – Rest of Asia-Pacific
– LAMEA
– – Brazil
– – Saudi Arabia
– – Rest of LAMEA
– – U.S.
– – Rest of North America
– Europe
– – UK
– – Germany
– – France
– – Italy
– – Spain
– – Rest of Europe
– Asia-Pacific
– – Japan
– – China
– – Australia
– – Rest of Asia-Pacific
– LAMEA
– – Brazil
– – Saudi Arabia
– – Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE
REPORT
–
Aprecia Pharmaceuticals
– GlaxoSmithKline Plc.
– Hewlett Packard Caribe, BV, LLC
– 3D Printer Drug Machine
– FabRx Ltd.
– GlaxoSmithKline Plc.
– Hewlett Packard Caribe, BV, LLC
– 3D Printer Drug Machine
– FabRx Ltd.
LIST OF ORGANIZATIONS PROFILED IN
THE REPORT
–
UCL School of Pharmacy
– University of Glasgow
– University College London
– The University of Nottingham
– National University of Singapore
– University of Glasgow
– University College London
– The University of Nottingham
– National University of Singapore
LIST OF OTHER ORGANIZATIONS IN THE
VALUE CHAIN (These players are not profiled in the report, but can be included
on client request.)
–
University of Michigan
– bo Akademi University
– University of Sheffield
– bo Akademi University
– University of Sheffield
Access Complete Research Report with TOC @ https://www.kdmarketinsights.com/product/3d-printed-drugs-market-amr
Table of Content
CHAPTER 1 INTRODUCTION
1.1.
REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
CHAPTER 2 EXECUTIVE SUMMARY
2.1.
KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE
2.2. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1.
MARKET DEFINITION AND SCOPE
3.2. 3D PRINTED DRUGS: AN OVERVIEW
3.2. 3D PRINTED DRUGS: AN OVERVIEW
3.2.1.
Why 3D printed drugs?
3.2.2. Indications
3.2.2. Indications
3.2.2.1.
Dysphagia: target population
3.2.2.2. Other indications
3.2.2.2. Other indications
3.2.3.
What to expect?
3.2.3.1.
Customized dosage forms
3.2.3.1.1.
Color
3.2.3.1.2. Flavor
3.2.3.1.3. Shape
3.2.3.1.4. Personalized medications
3.2.3.1.2. Flavor
3.2.3.1.3. Shape
3.2.3.1.4. Personalized medications
3.2.3.2.
Release of complex drugs
3.2.4.
3D drug printing technologies
3.2.4.1.
Inkjet printing
3.2.4.2. Direct-write
3.2.4.3. Zip dose
3.2.4.4. Thermal inkjet (TIJ) printing
3.2.4.5. Fused deposition modelling (FDM)
3.2.4.6. Powder bed printing
3.2.4.7. Stereolithography (SLA)
3.2.4.2. Direct-write
3.2.4.3. Zip dose
3.2.4.4. Thermal inkjet (TIJ) printing
3.2.4.5. Fused deposition modelling (FDM)
3.2.4.6. Powder bed printing
3.2.4.7. Stereolithography (SLA)
3.3.
MARKET DYNAMICS
3.3.1.
Drivers
3.3.1.1.
High demand of instantaneous soluble tablets
3.3.1.2. Increasing prevalence of dysphagia
3.3.1.3. Growing usage of 3D printing
3.3.1.4. Increasing adoption of personalized drugs
3.3.1.2. Increasing prevalence of dysphagia
3.3.1.3. Growing usage of 3D printing
3.3.1.4. Increasing adoption of personalized drugs
3.3.2.
Restraints
3.3.2.1.
3D printing could be used to print illegal drugs
3.3.2.2. Stringent government regulations for 3D printed products
3.3.2.2. Stringent government regulations for 3D printed products
3.3.3.
Opportunities
3.3.3.1.
Growing healthcare infrastructure and increase in healthcare investment in
emerging nations
3.3.3.2. Rising awareness about the 3D printing technology
3.3.3.2. Rising awareness about the 3D printing technology
3.3.4.
Impact analysis
CHAPTER 4 SPRITAM: 3D PRINTED DRUGS
MARKET
4.1.
OVERVIEW
4.1.1.
Key market trends
4.1.2. Growth factors and opportunities
4.1.2. Growth factors and opportunities
4.2.
MARKET SIZE AND FORECAST
4.3. BY GEOGRAPHY
4.3. BY GEOGRAPHY
4.3.1.
U.S.
4.3.1.1.
Key market trends
4.3.1.2. Growth factors and opportunities
4.3.1.3. Market size and forecast
4.3.1.2. Growth factors and opportunities
4.3.1.3. Market size and forecast
4.3.2.
Rest of World
4.3.2.1.
Growth factors and opportunities
4.3.2.2. Market size and forecast
4.3.2.2. Market size and forecast
CHAPTER 5 OTHER 3D PRINTED DRUGS
POTENTIAL MARKET, BY SCENARIO
5.1.
OVERVIEW
5.1.1.
Market size and forecast
5.2.
LOW GROWTH SCENARIO
5.2.1.
Market size and forecast
5.3.
MODERATE GROWTH SCENARIO
5.3.1.
Market size and forecast
5.4.
HIGH GROWTH SCENARIO
5.4.1.
Market size and forecast
CHAPTER 6 OTHER 3D PRINTED DRUGS
POTENTIAL MARKET, BY REGION
6.1.
OVERVIEW
6.2. NORTH AMERICA
6.2. NORTH AMERICA
6.2.1.
Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.4. U.S.
6.2.5. Rest of North America
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.4. U.S.
6.2.5. Rest of North America
6.3.
EUROPE
6.3.1.
Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.4. UK
6.3.5. Germany
6.3.6. France
6.3.7. Italy
6.3.8. Spain
6.3.9. Rest of Europe
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.4. UK
6.3.5. Germany
6.3.6. France
6.3.7. Italy
6.3.8. Spain
6.3.9. Rest of Europe
6.4.
ASIA-PACIFIC
6.4.1.
Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.4. Japan
6.4.5. China
6.4.6. Australia
6.4.7. Rest of Asia-Pacific
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.4. Japan
6.4.5. China
6.4.6. Australia
6.4.7. Rest of Asia-Pacific
6.5.
LAMEA
6.5.1.
Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.4. Brazil
6.5.5. Saudi Arabia
6.5.6. Rest of LAMEA
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.4. Brazil
6.5.5. Saudi Arabia
6.5.6. Rest of LAMEA
CHAPTER 7 COMPANY PROFILES
7.1.
APRECIA PHARMACEUTICALS COMPANY
7.1.1.
Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Key strategic moves and developments
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Key strategic moves and developments
7.2.
FABRX LTD.
7.2.1.
Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.2. Company snapshot
7.2.3. Operating business segments
7.3.
GLAXOSMITHKLINE PLC
7.3.1.
Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Business performance
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Business performance
Continue @...
About Us:
KD Market
Insights offers a
comprehensive database of syndicated research studies, customized reports, and
consulting services. These reports are created to help in making smart, instant
and crucial decisions based on extensive and in-depth quantitative information,
supported by extensive analysis and industry insights. Our dedicated in-house
team ensures the reports satisfy the requirement of the client. We aim at
providing value service to our clients. Our reports are backed by extensive
industry coverage and is made sure to give importance to the specific needs of
our clients. The main idea is to enable our clients to make an informed
decision, by keeping them and ourselves up to date with the latest trends in
the market.
Contact Us:
KD Market Insights
150 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: sales@kdmarketinsights.com
Website: www.kdmarketinsights.com
KD Market Insights
150 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: sales@kdmarketinsights.com
Website: www.kdmarketinsights.com
No comments:
Post a Comment